1% and the undetectable rate of HBV DNA (by real-time polymerase chain reaction) was 90.1%. The changes of total bilirubin, albumin, platelet count, MELD score, and CP score between the two time points were from 2.1 ±3.2 to 1.3±1.0 mg/dL (p=0.014), from 3.6±0.6 to 4.1±0.5 g/dL (p<0.001), from 102±44 to 110±48xl000>/mm3 (p=0.013), from Mitomycin C 9.2±5.2 to 6.7±5.2 (p<0.001), and from 6.4±1.8 to 5.5±1.0 (p<0.001), respectively. The distribution of CP class at baseline was 66.7% in A, 26.1% in B, and 7.2% in C. The distribution of CP class at 2 year after ETV treatment was 88.3% in A, 10.8% in B, and 0.9% in C. The improvement of CP class between the two time points was significant (p<0.001). The changes www.selleckchem.com/products/bmn-673.html of

APRI score, FIB-4 index, and FI between the two time points were from 3.2±2.4 to 1.1±0.9 (p<0.001), from 6.8±4.1 to 4.3±3.0 (p<0.001), and from 3.4±0.9 to 2.9±0.9 (p<0.001), respectively. Conclusions: Entecavir improves not only liver function but also fibrosis in patients with HBV-associated LC for long-term treatment. Disclosures: The following people have nothing to disclose: Hyeonsu Park, Oh Sang Kwon, Jong Joon Lee, Young Kul Jung, Duck Joo Choi, Yun Soo Kim, Ju Hyun Kim BACKGROUND/AIM Hepatitis B early antigen (HBeAg) seroconversion (SC) is the principal treatment endpoint in HBeAg-positive patients

and the main therapeutic objective after viral suppression. Uncertain SC rates (SCR) in Asian patients treated with modern nucleos(t)ide analogs hamper prediction of treatment duration causing patient trepidation. We conducted a single-center study to evaluate SCR and virologic response (VR) among Asians and non-Asians treated with ETV or TDF. METHODS In HBeAg-positive patients treated with ETV or TDF monotherapy we estimated the cumulative probability of SC (HBeAb synthesis and HBeAg loss) in 1 87 patients (83% Asian) and VR (serum HBV DNA <1000IU/mL) in 145 patients

(78% Asian). Cumulative probability of SC and VR were calculated by ethnicity SPTLC1 and compared using the log-rank test. Cox regression modeled the risk of SC and VR; covariates included gender, age, LAM exposure, HBV genotype and baseline ALT. RESULTS The respective cumulative probabilities of SC on ETV or TDF at year 1, 2, 3, 4 and 5 were 5%, 10%, 16%, 25% and 35% in Asians, and 14%, 39%, 39%, 55% and 55% in non-Asians; differing significantly after year 1 (p<0.002). After adjusting for covariates the probability of SC remained significantly lower in Asians versus non-Asians (HR 0.33, 95%Cl p=0.004). In non-Asians, 2 and 3 year SCR were similar to rates reported in clinical trials. The cumulative probabilities of VR on ETV or TDF at year 1, 2, 3 and 4 were 59%, 77%, 84% and 92% in Asians, and 84%, 88% and 100% in non-Asians, which differed significantly (p<0.05) only in the univariate analysis.